On Monday, H.C. Wainwright initiated coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) stock with a Buy rating and a price target of $10.00. The firm highlighted Lexicon's commitment to innovative mechanistic approaches in the commercial stage of development.
Lexicon, a commercial-stage biotechnology company, leverages its Genome5000 technology to develop orally delivered small molecule inhibitors. This technology enables the identification of druggable genes through knockout mouse models.
Lexicon has identified over 100 proteins with therapeutic potential across various indications. The company is advancing three candidates in its pipeline. The first is sotagliflozin, a dual sodium/glucose cotransporter inhibitor, already commercialized in the U.S. for heart failure under the name INPEFA, which was approved in May 2023. In Europe, it is marketed for type 1 diabetes as Zynquista, approved in April 2019.
Sotagliflozin is also in late-stage clinical development for type 1 diabetes patients with chronic kidney disease, with a resubmission of its New Drug Application (NDA) expected in the second half of 2024, and for patients with hypertrophic cardiomyopathy, with Phase 3 trials anticipated to begin in the second half of 2024.
The second candidate, LX9211, an inhibitor targeting adaptor-associated protein kinase 1, is under Phase 2 evaluation for diabetic peripheral neuropathic pain, with topline data expected in the second quarter of 2025. The third, LX9851, is an inhibitor aimed at treating obesity and weight management and is gearing up for Phase 1 evaluation.
H.C. Wainwright's coverage underscores the potential of Lexicon's diverse pipeline, the commercial growth prospects of INPEFA, and the late-stage opportunities for sotagliflozin and LX9211.
The firm believes that Lexicon's capability to progress its assets from early discovery to the market positions the company as a valuable, fully integrated biopharmaceutical entity with a steady stream of clinical, regulatory, and commercial catalysts.
In other recent news, Lexicon Pharmaceuticals has been the focus of several significant developments. Piper Sandler reaffirmed its Overweight rating and a price target of $10.00 on Lexicon's stock, buoyed by the anticipation of a noteworthy year ahead for the company.
The firm's confidence stems from Lexicon's pipeline, particularly the expected launch of INPEFA for heart failure in the second half of 2024, and the expansion of sotagliflozin into hypertrophic cardiomyopathy and type 1 diabetes with chronic kidney disease by mid-2024.
Moreover, Lexicon reported a net loss of $48.4 million in the first quarter of 2024, with revenue of $1.1 million. The company's CEO, Lonnel Coats (LON:COA), has also announced his retirement effective July 7th, 2024. Despite the net loss, the company raised $250 million in an oversubscribed offering to support their programs.
Lexicon provided full-year expense guidance, projecting R&D expenses between $70 million to $80 million and total operating expenses ranging from $210 million to $235 million. This comes as the company expects its existing capital and product revenues to support operations until 2026. These are among the recent developments for Lexicon Pharmaceuticals.
InvestingPro Insights
As Lexicon Pharmaceuticals (NASDAQ:LXRX) continues to make strides in the biotechnology industry, recent data from InvestingPro provides additional context for investors considering the company's prospects. With a market cap of approximately $657.92 million USD, Lexicon holds a significant position in the market. Despite challenges such as rapidly depleting cash reserves and weak gross profit margins, with a Gross Profit Margin of -2555.8% over the last twelve months as of Q1 2024, the company has managed to maintain a strong cash position relative to its debt. This is underscored by an impressive revenue growth of 1733.33% during the same period, indicating potential for future expansion.
InvestingPro Tips indicate that while analysts are not expecting profitability this year, they do foresee sales growth in the current year. Additionally, Lexicon's liquid assets exceed its short-term obligations, providing some financial stability in the near term. However, it's important to note that Lexicon is trading at a high revenue valuation multiple, suggesting that the market has high expectations for the company's future performance. With a price uptick of 43.31% over the last six months, investors appear to be responding positively to Lexicon's prospects.
For those looking to delve deeper into Lexicon's financials and future outlook, InvestingPro offers a wealth of additional tips. By using the coupon code PRONEWS24, readers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing access to a total of 10 InvestingPro Tips for Lexicon Pharmaceuticals, which may further inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.